406 related articles for article (PubMed ID: 24875621)
21. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
Grabowska MM; Kelly SM; Reese AL; Cates JM; Case TC; Zhang J; DeGraff DJ; Strand DW; Miller NL; Clark PE; Hayward SW; Gronostajski RM; Anderson PD; Matusik RJ
Endocrinology; 2016 Mar; 157(3):1094-109. PubMed ID: 26677878
[TBL] [Abstract][Full Text] [Related]
22. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
23. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
[TBL] [Abstract][Full Text] [Related]
24. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
25. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
26. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
27. Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.
Leach DA; Panagopoulos V; Nash C; Bevan C; Thomson AA; Selth LA; Buchanan G
Mol Cell Endocrinol; 2017 Jan; 439():261-272. PubMed ID: 27634452
[TBL] [Abstract][Full Text] [Related]
28. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.
Grabowska MM; Elliott AD; DeGraff DJ; Anderson PD; Anumanthan G; Yamashita H; Sun Q; Friedman DB; Hachey DL; Yu X; Sheehan JH; Ahn JM; Raj GV; Piston DW; Gronostajski RM; Matusik RJ
Mol Endocrinol; 2014 Jun; 28(6):949-64. PubMed ID: 24801505
[TBL] [Abstract][Full Text] [Related]
29. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
30. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.
Taslim C; Chen Z; Huang K; Huang TH; Wang Q; Lin S
Nucleic Acids Res; 2012 Jun; 40(11):4754-64. PubMed ID: 22344698
[TBL] [Abstract][Full Text] [Related]
32. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
[TBL] [Abstract][Full Text] [Related]
33. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
Pomerantz MM; Li F; Takeda DY; Lenci R; Chonkar A; Chabot M; Cejas P; Vazquez F; Cook J; Shivdasani RA; Bowden M; Lis R; Hahn WC; Kantoff PW; Brown M; Loda M; Long HW; Freedman ML
Nat Genet; 2015 Nov; 47(11):1346-51. PubMed ID: 26457646
[TBL] [Abstract][Full Text] [Related]
34. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.
Hwang JH; Arafeh R; Seo JH; Baca SC; Ludwig M; Arnoff TE; Sawyer L; Richter C; Tape S; Bergom HE; McSweeney S; Rennhack JP; Klingenberg SA; Cheung ATM; Kwon J; So J; Kregel S; Van Allen EM; Drake JM; Freedman ML; Hahn WC
Elife; 2022 May; 11():. PubMed ID: 35550030
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
Wang Q; Li W; Zhang Y; Yuan X; Xu K; Yu J; Chen Z; Beroukhim R; Wang H; Lupien M; Wu T; Regan MM; Meyer CA; Carroll JS; Manrai AK; Jänne OA; Balk SP; Mehra R; Han B; Chinnaiyan AM; Rubin MA; True L; Fiorentino M; Fiore C; Loda M; Kantoff PW; Liu XS; Brown M
Cell; 2009 Jul; 138(2):245-56. PubMed ID: 19632176
[TBL] [Abstract][Full Text] [Related]
36. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Zhao Y; Tindall DJ; Huang H
Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
[TBL] [Abstract][Full Text] [Related]
37. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
38. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
39. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
40. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Chan SC; Selth LA; Li Y; Nyquist MD; Miao L; Bradner JE; Raj GV; Tilley WD; Dehm SM
Nucleic Acids Res; 2015 Jul; 43(12):5880-97. PubMed ID: 25908785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
